Advanced

Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.

Schultz, Kristofer LU ; Nilsson, K; Nielsen, J E; Lindquist, S G; Hjermind, L E; Andersen, B B; Wallin, A; Nilsson, C and Petersén, Åsa LU (2010) In European Journal of Neurology 17. p.456-460
Abstract
Background: Previous studies have indicated that transthyretin (TTR) levels in cerebrospinal fluid (CSF) are altered in depression and dementia. The present study aimed to investigate whether CSF TTR can be used to discriminate between patients with Alzheimer's disease (AD) and patients with dementia with Lewy bodies (DLB) with or without medication, as well as to reveal whether CSF TTR correlates with depression in dementia. Methods: CSF samples from 59 patients with AD, 13 patients with DLB and 13 healthy controls were collected, and biochemical analysis was performed. Subjects were assessed for the presence of depression. Results: No significant differences in CSF TTR were found between AD, DLB, and control subjects or between depressed... (More)
Background: Previous studies have indicated that transthyretin (TTR) levels in cerebrospinal fluid (CSF) are altered in depression and dementia. The present study aimed to investigate whether CSF TTR can be used to discriminate between patients with Alzheimer's disease (AD) and patients with dementia with Lewy bodies (DLB) with or without medication, as well as to reveal whether CSF TTR correlates with depression in dementia. Methods: CSF samples from 59 patients with AD, 13 patients with DLB and 13 healthy controls were collected, and biochemical analysis was performed. Subjects were assessed for the presence of depression. Results: No significant differences in CSF TTR were found between AD, DLB, and control subjects or between depressed and non-depressed dementia patients. Interestingly, we found a significant reduction in CSF TTR (14%) in AD patients who were medicated with cholinesterase inhibitors compared to those AD patients who were not. Conclusions: Significant reductions in CSF TTR were found after cholinesterase inhibitor treatment in patients with AD compared to untreated individuals. CSF TTR was unaltered in patients with DLB and had no relationship to depression in the present cohort with dementias. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Neurology
volume
17
pages
456 - 460
publisher
Wiley-Blackwell
external identifiers
  • wos:000274907000023
  • pmid:19922456
  • scopus:77649165856
ISSN
1351-5101
DOI
10.1111/j.1468-1331.2009.02841.x
language
English
LU publication?
yes
id
5931b470-67ad-4fb4-9661-11ea9d8992ce (old id 1511810)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19922456?dopt=Abstract
date added to LUP
2009-12-04 15:04:16
date last changed
2018-05-29 10:36:52
@article{5931b470-67ad-4fb4-9661-11ea9d8992ce,
  abstract     = {Background: Previous studies have indicated that transthyretin (TTR) levels in cerebrospinal fluid (CSF) are altered in depression and dementia. The present study aimed to investigate whether CSF TTR can be used to discriminate between patients with Alzheimer's disease (AD) and patients with dementia with Lewy bodies (DLB) with or without medication, as well as to reveal whether CSF TTR correlates with depression in dementia. Methods: CSF samples from 59 patients with AD, 13 patients with DLB and 13 healthy controls were collected, and biochemical analysis was performed. Subjects were assessed for the presence of depression. Results: No significant differences in CSF TTR were found between AD, DLB, and control subjects or between depressed and non-depressed dementia patients. Interestingly, we found a significant reduction in CSF TTR (14%) in AD patients who were medicated with cholinesterase inhibitors compared to those AD patients who were not. Conclusions: Significant reductions in CSF TTR were found after cholinesterase inhibitor treatment in patients with AD compared to untreated individuals. CSF TTR was unaltered in patients with DLB and had no relationship to depression in the present cohort with dementias.},
  author       = {Schultz, Kristofer and Nilsson, K and Nielsen, J E and Lindquist, S G and Hjermind, L E and Andersen, B B and Wallin, A and Nilsson, C and Petersén, Åsa},
  issn         = {1351-5101},
  language     = {eng},
  pages        = {456--460},
  publisher    = {Wiley-Blackwell},
  series       = {European Journal of Neurology},
  title        = {Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.},
  url          = {http://dx.doi.org/10.1111/j.1468-1331.2009.02841.x},
  volume       = {17},
  year         = {2010},
}